Novel agents such as sodium glucose cotransporter-2 (SGLT-2) inhibitors, non-steroidal selective mineralocorticoid receptor antagonists and endothelin A receptor antagonists have recently been demonstrated to improve clinical outcomes and lower blood pressure, and are likely to be used in the routine management of DKD in the future [4]. The gene discussed is NR3C2; the disease is diabetic kidney disease.